Recommendations for specific patients can be quite different. We need to
distinguish (both in the ontology and also in the decision support interface):
"high-priority" recommendations: for patients phenotypes that should
prompt alteration of dosing (such as poor or ultrarapid metabolizer of CYP2D6,
and
homozygous or heterozygous TPMT deficiency).
"standard treatment" recommendations: for patients that ususally need the
standard dose / treatment regime (e.g., they have the common allele).
This should be captured in the spreadsheet in an extra column, in the ontology
(via an annotation property) and in the user interface (e.g., a red exclamation
mark in the header of "high-priority" recommendations, a green "hakerl" for
"standard treatment" recommendations)
Original issue reported on code.google.com by matthias...@gmail.com on 15 Jan 2014 at 11:11
Original issue reported on code.google.com by
matthias...@gmail.com
on 15 Jan 2014 at 11:11